Lifecore Biomedical, Inc. (LFCR)
NASDAQ:LFCR
Want to see LFCR full AI Analyst Report?
LFCR Stock Chart & Stats
$7.71
-$0.17(-2.79%)
At close: 4:00 PM EST
$7.71
-$0.17(-2.79%)
Day’s Range― - ―
52-Week Range$3.63 - $8.98
Previous CloseN/A
Volume140.23K
Average Volume (3M)228.45K
Market Cap
$184.92M
Enterprise Value$314.27M
Total Cash (Recent Filing)$20.80M
Total Debt (Recent Filing)$150.14M
Price to Earnings (P/E)―
Beta1.76
Next Earnings
Aug 06, 2026EPS Estimate
-0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.03
Shares Outstanding37,509,407
10 Day Avg. Volume206,545
30 Day Avg. Volume228,447
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)175.14
Price to Sales (P/S)1.82
P/FCF Ratio-17.18
Enterprise Value/Market Cap1.70
Enterprise Value/Revenue2.33
Enterprise Value/Gross Profit7.46
Enterprise Value/Ebitda115.24
Forecast
1Y Price Target
$6.67Price Target Upside-13.53% Downside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.02
Revenue Forecast (FY)$122.23M
Bulls Say, Bears Say
Bulls Say
Commercial Manufacturing WinsMultiple U.S. commercial manufacturing site transfer agreements should drive higher revenue and improve capacity utilization as production moves from overseas to the company's contract facilities.
Profitability And Cash GenerationSignificant cuts to selling and administrative expenses alongside consistent positive cash flow strengthen financial stability and reduce the need for an immediate capital raise.
Strategic Positioning And Industry TailwindsBeing a fully integrated CDMO with sterile injectable and hyaluronic acid expertise positions the company to capture demand from growing injectable drug pipelines, outsourcing trends, and onshoring.
Bears Say
Conservative Guidance And Elevated VolatilityConservative management guidance combined with an aggressive-risk classification signals potential for elevated share price volatility and investor uncertainty.
Customer Concentration And Lost AccountsLoss of a key customer and reduced sales to a top buyer due to supplier strategy changes create material revenue headwinds and increase uncertainty around future sales levels.
Delayed Commercialization TimelinesPushed commercialization timelines for key late-stage programs postpone the expected revenue inflection and raise pressure on future growth assumptions.
Lifecore Biomedical News
LFCR FAQ
What was Lifecore Biomedical, Inc.’s price range in the past 12 months?
Lifecore Biomedical, Inc. lowest stock price was $3.63 and its highest was $8.98 in the past 12 months.
What is Lifecore Biomedical, Inc.’s market cap?
Lifecore Biomedical, Inc.’s market cap is $184.92M.
When is Lifecore Biomedical, Inc.’s upcoming earnings report date?
Lifecore Biomedical, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 74 days.
How were Lifecore Biomedical, Inc.’s earnings last quarter?
Currently, no data Available
Is Lifecore Biomedical, Inc. overvalued?
According to Wall Street analysts Lifecore Biomedical, Inc.’s price is currently Overvalued.
Does Lifecore Biomedical, Inc. pay dividends?
Lifecore Biomedical, Inc. does not currently pay dividends.
What is Lifecore Biomedical, Inc.’s EPS estimate?
Lifecore Biomedical, Inc.’s EPS estimate is -0.22.
How many shares outstanding does Lifecore Biomedical, Inc. have?
Lifecore Biomedical, Inc. has 37,509,407 shares outstanding.
What happened to Lifecore Biomedical, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Lifecore Biomedical, Inc.?
Currently, no hedge funds are holding shares in LFCR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Lifecore Biomedical Stock Smart Score
Company Description
Lifecore Biomedical, Inc.
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. It operates through Lifecore, Curation Foods, and Other segments. The Lifecore segment engages in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, including technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. This segment sells its non-HA products for medical use primarily in the ophthalmic, orthopedic, and other markets. The Curation Foods segment engages in processing, marketing, and selling of olive oils and wine vinegars under the O brand; and guacamole and avocado food products under the Yucatan and Cabo Fresh brands, as well as various private labels. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was incorporated in 1986 and is headquartered in Santa Maria, California.
LFCR Stock 12 Month Forecast
Average Price Target
$6.67
▼(-13.53% Downside)
Technical Analysis
Ironwood Pharma
―
Cumberland Pharmaceuticals
―
China SXT Pharmaceuticals
―
Journey Medical Corp
―
BioAge Labs, Inc.
―
Ownership Overview
17.21% Insiders
6.25% Mutual Funds
46.64% Other Institutional Investors
23.26% Public Companies and
Individual Investors